New drug duo aims to shield diabetic kidneys
NCT ID NCT06072326
Summary
This study is testing whether combining two existing drugs (dapagliflozin and SC0062) provides better protection for the kidneys than either drug alone in adults with type 1 diabetes who have early signs of kidney damage. The trial will involve 36 participants who will try different drug combinations over 24 weeks to see which best reduces protein in urine, a key sign of kidney stress. The goal is to find treatments that slow kidney disease progression in people with type 1 diabetes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS WITH DIABETIC NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam University Academic Center
Amsterdam, North Holland, 1081 HV, Netherlands
Contact
-
Regionshospitalet Gødstrup
Herning, 7400, Denmark
Contact
-
Steno Diabetes Center Aarhus
Aarhus, 8200, Denmark
Contact
-
Steno Diabetes Center Copenhagen
Copenhagen, 2730 Herlev, Denmark
Contact
-
Turku University Hospital
Turku, 20520, Finland
Contact
-
University Medical Center Groningen
Groningen, Provincie Groningen, 9700 RB, Netherlands
Contact
-
University of Helsinki
Helsinki, Uusimaa, 00029 HUS, Finland
Contact
Conditions
Explore the condition pages connected to this study.